ARCT
Price
$18.51
Change
+$1.03 (+5.89%)
Updated
Aug 22 closing price
Capitalization
502.63M
72 days until earnings call
MGNX
Price
$1.69
Change
+$0.25 (+17.36%)
Updated
Aug 22 closing price
Capitalization
106.82M
78 days until earnings call
Interact to see
Advertisement

ARCT vs MGNX

Header iconARCT vs MGNX Comparison
Open Charts ARCT vs MGNXBanner chart's image
Arcturus Therapeutics Holdings
Price$18.51
Change+$1.03 (+5.89%)
Volume$505.29K
Capitalization502.63M
MacroGenics
Price$1.69
Change+$0.25 (+17.36%)
Volume$1.53M
Capitalization106.82M
ARCT vs MGNX Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. MGNX commentary
Aug 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a StrongBuy and MGNX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 25, 2025
Stock price -- (ARCT: $18.51 vs. MGNX: $1.69)
Brand notoriety: ARCT and MGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 87% vs. MGNX: 176%
Market capitalization -- ARCT: $502.63M vs. MGNX: $106.82M
ARCT [@Biotechnology] is valued at $502.63M. MGNX’s [@Biotechnology] market capitalization is $106.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.31B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileMGNX’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • MGNX’s FA Score: 0 green, 5 red.
According to our system of comparison, ARCT is a better buy in the long-term than MGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 6 TA indicator(s) are bullish while MGNX’s TA Score has 4 bullish TA indicator(s).

  • ARCT’s TA Score: 6 bullish, 4 bearish.
  • MGNX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ARCT is a better buy in the short-term than MGNX.

Price Growth

ARCT (@Biotechnology) experienced а -4.98% price change this week, while MGNX (@Biotechnology) price change was +6.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.57%. For the same industry, the average monthly price growth was +18.06%, and the average quarterly price growth was +26.94%.

Reported Earning Dates

ARCT is expected to report earnings on Nov 05, 2025.

MGNX is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($503M) has a higher market cap than MGNX($107M). ARCT YTD gains are higher at: 9.075 vs. MGNX (-48.000). MGNX has higher annual earnings (EBITDA): -26.91M vs. ARCT (-54.54M). ARCT has more cash in the bank: 196M vs. MGNX (176M). ARCT has less debt than MGNX: ARCT (27M) vs MGNX (37.2M). MGNX has higher revenues than ARCT: MGNX (164M) vs ARCT (110M).
ARCTMGNXARCT / MGNX
Capitalization503M107M470%
EBITDA-54.54M-26.91M203%
Gain YTD9.075-48.000-19%
P/E RatioN/AN/A-
Revenue110M164M67%
Total Cash196M176M111%
Total Debt27M37.2M73%
FUNDAMENTALS RATINGS
ARCT vs MGNX: Fundamental Ratings
ARCT
MGNX
OUTLOOK RATING
1..100
3766
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
4264
P/E GROWTH RATING
1..100
10095
SEASONALITY SCORE
1..100
4650

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (45) in the Pharmaceuticals Major industry is somewhat better than the same rating for MGNX (79) in the Biotechnology industry. This means that ARCT’s stock grew somewhat faster than MGNX’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as MGNX (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to MGNX’s over the last 12 months.

ARCT's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as MGNX (98) in the Biotechnology industry. This means that ARCT’s stock grew similarly to MGNX’s over the last 12 months.

ARCT's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as MGNX (64) in the Biotechnology industry. This means that ARCT’s stock grew similarly to MGNX’s over the last 12 months.

MGNX's P/E Growth Rating (95) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that MGNX’s stock grew similarly to ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTMGNX
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
82%
MACD
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 20 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 7 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
Aroon
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RRSVX15.640.59
+3.92%
RBC Small Cap Value R6
VVONX23.470.61
+2.67%
Invesco Value Opportunities R5
MCGAX10.780.21
+1.99%
Transamerica Mid Cap Growth A
AEDCX33.020.49
+1.51%
Invesco International Value C
ACVDX11.160.14
+1.27%
American Century International Val R6

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with RGNX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+5.89%
RGNX - ARCT
51%
Loosely correlated
+11.10%
BEAM - ARCT
51%
Loosely correlated
+3.94%
CLDX - ARCT
50%
Loosely correlated
+2.00%
AXON - ARCT
49%
Loosely correlated
+0.36%
MGNX - ARCT
47%
Loosely correlated
+17.36%
More

MGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MGNX has been loosely correlated with XNCR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if MGNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MGNX
1D Price
Change %
MGNX100%
+17.36%
XNCR - MGNX
54%
Loosely correlated
+13.04%
CRBU - MGNX
54%
Loosely correlated
+0.54%
RGNX - MGNX
53%
Loosely correlated
+11.10%
FATE - MGNX
52%
Loosely correlated
+3.60%
BEAM - MGNX
51%
Loosely correlated
+3.94%
More